During the past 7 years the UCCRC Flow Cytometry Facility has been under the direction of Dr. Jeffrey Bluestone. He has been responsible for the overall growth and direction of the facility. In 1993, Ms Julie Auger joined the facility as Technical Director. Her extensive experience in flow cytometry elevated the quality and extent of the services resulting in more than a doubling of the use of the Facility since her arrival. The facility now provides advanced technologies to basic and clinical researchers and extensive support to all cancer members. During the past year, there has been a growing need for centralized immunohistochemistry and in situ services for cancer center members. A recent survey showed that more than 25 cancer center members expressed strong interest in developing an immunohistochemistry core. To that end, the Flow Cytometry Facility had begun to provide limited immunohistochemistry services to fill this increasing need. This has been possible due to the common use of many reagents for both flow cytometry and immunohistochemistry and our ability to link these two approaches to answer research questions. More recently, the University of Chicago has been fortunate to have recruited Dr. David Baunoch to the Department of Pathology. Dr. Baunoch is a well established pathologist with a strong background in both immunohistochemistry and in situ analyses. He has agreed to lead the immunohistochemistry /in situ component of the core and establish a first-rate facility for cancer center use. The addition of these technologies to the UCCRC Flow Cytometry Core will provide a state-of- the-art facility for broad-based research in immunophenotyping, DNA/cell cycle analysis, and apoptosis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014599-23
Application #
5206678
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
23
Fiscal Year
1996
Total Cost
Indirect Cost
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351
Wei, Jiangbo; Liu, Fange; Lu, Zhike et al. (2018) Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell 71:973-985.e5

Showing the most recent 10 out of 668 publications